Chimeric Antigen Receptor T Cell O&D-001 Targeting Bcma And Gprc5D
Relapsed or Refractory Multiple Myeloma
O&D BioTech Group CO., LimitedCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
16 Active assets in the Relapsed or Refractory Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
qls32015 Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
sg301 Hangzhou Sumgen Biotech Co., Ltd. | Phase 3 | B |
Encorafenib University of Heidelberg Medical Center | Phase 2 | B |
Mitoxantrone Second Affiliated Hospital of Soochow University | Phase 1/2 | CCC |
auy922 Novartis Pharmaceuticals | Phase 1/2 | CCC |
View all 27 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →